Pfenex Inc. (PFNX) Plunges 6.05%

Pfenex Inc. (PFNX) Plunges 6.05%

Pfenex Inc. (PFNX) had a rough trading day for Friday October 04 as shares tumbled 6.05%, or a loss of $-0.48 per share, to close at $7.46. After opening the day at $7.97, shares of Pfenex Inc. traded as high as $8.00 and as low as $6.96. Volume was 634,974 shares over 3,131 trades, against an average daily volume of n/a shares and a total float of 31.6 million.

As a result of the decline, Pfenex Inc. now has a market cap of $235.72 million. In the last year, shares of Pfenex Inc. have traded between a range of $10.20 and $3.13, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.

Pfenex Inc. is based out of San Diego, CA and has some 78 employees. Its CEO is Evert B. Schimmelpennink.

Pfenex Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

error: Content is protected !!